Answers are grounded in this paper and cite their sources.
The highly selective permeability of the blood-brain barrier (BBB) significantly restricts the effective delivery of therapeutic agents to the brain for treating central nervous system (CNS) disorders. Nanomaterial-based drug delivery strategies, leveraging the nanoscale size effects, tunable surface chemistry, and versatile functionalization capabilities of nanomaterials, offer promising opportunities to overcome this barrier. This review systematically outlines the intricate structure and physiological functions of the BBB. It primarily focuses on recent advances in various nanomaterials for brain-targeted delivery, including polymeric nanomaterials, lipid-based nanocarriers, inorganic nanomaterials, and carbon-based nanomaterials. Their ability to traverse the BBB through mechanisms such as passive diffusion, carrier-mediated transport, adsorptive-mediated transport, and receptor-mediated transport is summarized in detail. Although current research has demonstrated the feasibility of nanocarriers for BBB crossing, clinical translation still faces challenges, including suboptimal delivery efficiency, the heterogeneous nature of the BBB under pathological conditions, and complex preparation processes. Future efforts should focus on developing smart responsive carriers, constructing biomimetic delivery systems, and employing multi-mechanism synergistic strategies to advance nanomedicine from a state of "possibility" to "practicality", ultimately enabling precise diagnosis and treatment of CNS diseases.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: